Pathogenesis & Immunologic Targets

The Guthy-Jackson Charitable Foundation (GJCF) NMOSD Grand Rounds program aims to inform practicing neurology specialists as well as the broader spectrum of neurologists and allied healthcare providers regarding latest information in evidence-based science and medicine of NMOSD. This program features 12 essential topics addressed by experts in the field at a monthly interval. Organized and curated by GJCF advisors, this series of educational webinars enables continuing medical education (CME) credit. 

Session entitled “Pathogenesis & Immunologic Targets” is designed to update knowledge important for understanding pathogenesis and corresponding immunologic targets and mechanisms of action of approved NMOSD therapeutics. Application of this knowledge is intended to facilitate best clinical outcomes and minimize long-term disability in NMOSD.

Learning Objectives:
After completing this activity, learners will be able to:

1. Describe the role of B cells, T cells, and pathogenic antibodies in the pathogenesis of neuromyelitis optica spectrum disorder (NMOSD).
2. Compare current FDA-approved therapies for NMOSD based on mechanism of action and immunologic targets.
3. Explain the principles of immune tolerance and emerging therapeutic strategies aimed at selective immune modulation in NMOSD.

The estimated time to complete this activity is 1 hour.